Fragoso-Veloz J, Tapia R
Departamento de Neurociencias, Universidad Nacional Autónoma de México, México D.F.
Eur J Pharmacol. 1992 Oct 20;221(2-3):275-80. doi: 10.1016/0014-2999(92)90713-e.
The effect of N-methyl-D-aspartate (NMDA) and non-NMDA receptor antagonists on the generalized tonic-clonic convulsions and wet-dog shakes induced by the intraperitoneal (i.p.) or the intrahippocampal (i.h., stereotaxic microinjection into the CA1 region) administration of 4-aminopyridine (4-AP) was studied in rats. Pretreatment with NMDA competitive and non-competitive antagonists resulted in potent protection against the motor effects of both the i.p. and the i.h. administration of 4-AP. MK-801 (0.25 mg/kg i.p.) and 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP, 0.8 nmol intracerebroventricular, i.c.v.) showed the most powerful anticonvulsive effect, since they prevented the occurrence of generalized tonic convulsions and the death of the animals in convulsions after i.p. 4-AP. The i.c.v. injection (10 nmol) of the NMDA competitive antagonists 2-amino-5-phosphonopentanoate (AP-5) and 2-amino-5-phosphonoheptanoate (AP-7) also showed a clear though less potent protective effect. Similarly, the frequency of wet-dog shakes induced by i.h. 4-AP was markedly decreased by pretreating the animals with i.p. MK-801 or with i.c.v. CPP or AP-7. However, the co-injection of CPP with 4-AP failed to protect against the occurrence of wet-dog shakes. The i.c.v. pretreatment with the unselective antagonist, kynurenate (up to 68 nmol) or with the non-NMDA receptor antagonist, 6-cyano-7-nitroquinoxaline-2,3-dione (0.5 nmol), did not significantly modify the effects of 4-AP when administered either i.p. or i.h. We conclude that NMDA receptors are involved in the mechanism of the convulsive activity induced by 4-AP, probably because this drug induces the release of glutamate.
在大鼠中研究了N-甲基-D-天冬氨酸(NMDA)和非NMDA受体拮抗剂对腹腔注射(i.p.)或海马内注射(i.h.,立体定位微量注射至CA1区)4-氨基吡啶(4-AP)所诱导的全身强直阵挛性惊厥和湿狗样抖动的影响。用NMDA竞争性和非竞争性拮抗剂预处理可有效保护大鼠免受腹腔注射和海马内注射4-AP所产生的运动效应。MK-801(0.25mg/kg腹腔注射)和3-(2-羧基哌嗪-4-基)丙基-1-膦酸(CPP,0.8nmol脑室内注射,i.c.v.)显示出最强的抗惊厥作用,因为它们可预防腹腔注射4-AP后全身强直惊厥的发生以及惊厥动物的死亡。脑室内注射(10nmol)NMDA竞争性拮抗剂2-氨基-5-膦酰基戊酸(AP-5)和2-氨基-5-膦酰基庚酸(AP-7)也显示出明显但较弱的保护作用。同样,腹腔注射MK-801或脑室内注射CPP或AP-7预处理可使海马内注射4-AP所诱导的湿狗样抖动频率显著降低。然而,CPP与4-AP共同注射未能预防湿狗样抖动的发生。用非选择性拮抗剂犬尿烯酸(高达68nmol)或非NMDA受体拮抗剂6-氰基-7-硝基喹喔啉-2,3-二酮(0.5nmol)进行脑室内预处理,在腹腔注射或海马内注射4-AP时,并未显著改变4-AP的作用。我们得出结论,NMDA受体参与了4-AP诱导的惊厥活动机制,可能是因为该药物诱导了谷氨酸的释放。